First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Published:2021-01 Issue:10272 Volume:397 Page:375-386
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Baas Paul,Scherpereel Arnaud,Nowak Anna K,Fujimoto Nobukazu,Peters Solange,Tsao Anne S,Mansfield Aaron S,Popat Sanjay,Jahan Thierry,Antonia Scott,Oulkhouir Youssef,Bautista Yolanda,Cornelissen Robin,Greillier Laurent,Grossi Francesco,Kowalski Dariusz,Rodríguez-Cid Jerónimo,Aanur Praveen,Oukessou Abderrahim,Baudelet Christine,Zalcman Gérard

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database;Van Gerwen;Carcinogenesis,2019

2. Malignant pleural mesothelioma: a population-based study of survival;Milano;J Thorac Oncol,2010

3. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma;Billé;J Thorac Oncol,2016

4. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Baas;Ann Oncol,2015

5. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma;Scherpereel;Eur Respir J,2020

Cited by 757 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unleashing precision: A review of targeted approaches in pleural mesothelioma;Critical Reviews in Oncology/Hematology;2024-11

2. Malignant pleural mesothelioma: The disdained member of thoracic oncology!;World Journal of Experimental Medicine;2024-09-20

3. Survival prediction in peritoneal mesothelioma: a nomogram based on SEER data and a Chinese cohort;Frontiers in Endocrinology;2024-09-06

4. A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC;International Immunopharmacology;2024-09

5. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma;Lung Cancer;2024-09